Trials / Completed
CompletedNCT05965570
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
A Phase 1, Open-label, Fixed-sequence Study to Investigate the Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Insmed Incorporated · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to determine the effect of clarithromycin on the single-dose pharmacokinetics (PK) of brensocatib in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brensocatib | Oral tablets. |
| DRUG | Clarithromycin | Oral tablets. |
Timeline
- Start date
- 2023-07-28
- Primary completion
- 2023-09-22
- Completion
- 2023-09-22
- First posted
- 2023-07-28
- Last updated
- 2023-12-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05965570. Inclusion in this directory is not an endorsement.